Enovis Corporation (NYSE:ENOV) Given Consensus Rating of “Moderate Buy” by Analysts

by · The Cerbat Gem

Shares of Enovis Corporation (NYSE:ENOV – Get Free Report) have been assigned an average rating of “Moderate Buy” from the eight ratings firms that are covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell recommendation and seven have issued a buy recommendation on the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $46.7143.

A number of equities analysts recently issued reports on ENOV shares. Weiss Ratings restated a “sell (d-)” rating on shares of Enovis in a report on Wednesday, October 8th. Canaccord Genuity Group cut their price objective on Enovis from $58.00 to $50.00 and set a “buy” rating on the stock in a report on Wednesday, December 17th. Evercore ISI set a $40.00 target price on shares of Enovis in a report on Monday, January 5th. Wells Fargo & Company lifted their target price on shares of Enovis from $41.00 to $42.00 and gave the stock an “overweight” rating in a research report on Friday, November 7th. Finally, BTIG Research began coverage on shares of Enovis in a research report on Tuesday, January 6th. They issued a “buy” rating and a $41.00 price target for the company.

Check Out Our Latest Report on Enovis

Enovis Stock Performance

NYSE:ENOV opened at $29.75 on Monday. The company has a 50-day moving average of $28.36 and a 200-day moving average of $29.88. The firm has a market cap of $1.70 billion, a price-to-earnings ratio of -1.26 and a beta of 1.52. The company has a current ratio of 2.22, a quick ratio of 1.16 and a debt-to-equity ratio of 0.66. Enovis has a twelve month low of $25.47 and a twelve month high of $49.38.

Enovis (NYSE:ENOV – Get Free Report) last released its earnings results on Monday, January 8th. The company reported $0.59 EPS for the quarter. The business had revenue of $383.81 million during the quarter. Enovis had a negative net margin of 61.22% and a positive return on equity of 7.79%. Enovis has set its FY 2025 guidance at 3.100-3.250 EPS. Analysts forecast that Enovis will post 2.79 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Enovis news, insider John Kleckner acquired 2,468 shares of the firm’s stock in a transaction on Tuesday, November 25th. The stock was purchased at an average cost of $30.32 per share, for a total transaction of $74,829.76. Following the transaction, the insider owned 12,302 shares of the company’s stock, valued at $372,996.64. The trade was a 25.10% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Daniel A. Pryor sold 999 shares of Enovis stock in a transaction dated Tuesday, December 9th. The shares were sold at an average price of $27.20, for a total value of $27,172.80. Additional details regarding this sale are available in the official SEC disclosure. 2.70% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Enovis

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ENOV. Capital Fund Management S.A. bought a new stake in Enovis in the second quarter worth $1,682,000. Assenagon Asset Management S.A. acquired a new stake in shares of Enovis in the third quarter worth about $4,045,000. Rhumbline Advisers boosted its stake in shares of Enovis by 32.4% during the 2nd quarter. Rhumbline Advisers now owns 172,341 shares of the company’s stock worth $5,405,000 after acquiring an additional 42,138 shares in the last quarter. Boston Partners increased its holdings in shares of Enovis by 42.4% during the 2nd quarter. Boston Partners now owns 1,382,724 shares of the company’s stock valued at $43,352,000 after acquiring an additional 411,744 shares during the last quarter. Finally, Central Valley Advisors LLC raised its stake in shares of Enovis by 18.5% in the 2nd quarter. Central Valley Advisors LLC now owns 57,372 shares of the company’s stock valued at $1,799,000 after acquiring an additional 8,951 shares in the last quarter. Hedge funds and other institutional investors own 98.45% of the company’s stock.

Enovis Company Profile

(Get Free Report)

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.

Recommended Stories